Passage BIO Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THESECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39231 PASSAGE BIO,INC.(Exact Name of Registrant as Specified in its Charter) 82-2729751(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization)One Commerce Square2005 Market Street, 39thFloorPhiladelphia, PA(Address of principal executive offices) 19103(Zip Code) Registrant’s telephone number, including area code: (267) 866-0311 Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant wasrequired to file such reports), and (2)has been subject to such filing requirements for the past 90days. Yes⌧No◻ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or forsuch shorter period that the registrant was required to submit such files). Yes⌧No◻ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”“accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. Large accelerated filer◻Non-accelerated filer☒Emerging growth company◻ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section13(a)of theExchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ As of May 7, 2026, the registrant had 3,207,810 shares of common stock, $0.0001 par value per share, outstanding. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other thanstatements of historical facts contained in this Quarterly Report are forward-looking statements. In somecases, you can identify forward-looking statements by terms such as “aim,” “may,” “will,” “should,”“expect,” “forecast,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,”“estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions,although not all forward-looking statements contain these words. All statements other than statements ofhistorical fact contained in this Quarterly Report, including without limitation statements regarding ourplans to develop and commercialize our product candidates, our evaluation of potential next steps in theclinical development of our product candidates, the timing and results of our ongoing or plannedpreclinical studies and clinical trials, risks associated with clinical trials, including our ability to adequatelymanage clinical activities, unexpected concerns that may arise from additional data or analysis obtainedduring clinical trials, the timing of and our ability to obtain and maintain regulatory approvals, the clinicalutility of our product candidates, the potential development of other product candidates, ourcommercialization, marketing and manufacturing capabilities and strategy, our expectations about thewillingness of healthcare professionals to use our product candidates, the timing or amount of anypotential future milestone or royalty payments, the sufficiency of our cash and cash equivalents, ourexploration of potential strategic alternatives, the entry into or completion of any strategic alternativetransaction, the expected costs associated with termination benefits and the financial impact of ourrestructuring and reduction in workforce, general economic, industry and market conditions, includingfluctuating interest rates and inflation, changing tariff policies and trade restrictions, geopolitical conflicts,any future potential federal government shutdowns, instability in the global banking system, and the plansand objectives of management for future operations and capital expenditures are forward-lookingstatements. The forward-looking statements in this Quarterly Report are only predictions and are based largely on ourcurrent expectations and projections about future events and financial trends that we believe may affect ourbusiness, financial condition and results of operations. These forward-looking statements speak only as ofthe date of this Q